3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Gynecologic
1
Dermatologic
1
Conditions
Keratosis, Actinic
5
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Tuberous Sclerosis
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors Harboring NTRK Fusion
1
Small Cell Lung Carcinoma
1
Seizures
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, T-Cell
1
Lung Neoplasms
1
Leukemia
1
Lennox Gastaut Syndrome
1
Head and Neck Neoplasms
1
Epilepsies, Myoclonic
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Anemia
1
Advanced Solid Tumors
1
Adenocarcinoma of Lung
1
Interventions
10-propargyl-10-deazaaminopterin
6
Brentuximab Vedotin
5
romidepsin
3
Vitamin B 12
3
Rituximab
3
Folic Acid
3
Cyclophosphamide
3
tenalisib
2
cobomarsen
2
belinostat
2
Vincristine
2
Prednisone
2
Gemcitabine
2
Doxorubicin
2
zanubrutinib
1
zanolimumab
1
venetoclax
1
tislelizumab
1
quisinostat
1
pembrolizumab
1
mogamulizumab
1
fostamatinib
1
forodesine
1
fludarabine
1
enzastaurin
1
enzalutamide
1
duvelisib
1
denileukin diftitox
1
darinaparsin
1
cc-486
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, T-Cell
×
Solutions
×
Clear all
NCT04752826
2026-02-18
MK-3475-D20
BioInvent International AB
Phase 1/2
Recruiting
176 enrolled